When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
In a poster presentation at ASCO 2018, authors shared data from a recent study which suggest that testing and modulating the composition of the gut microbiome can have…
In the largest prospective study of angiogenesis in metastatic renal cell carcinoma (mRCC) patients to date, an Italian study yielded data that suggests sorafenib had no meaningful impact…
Some of the globe’s leading minds in medical research gathered at this year’s World Stem Cell Summit to discuss the recent developments, breakthroughs, and challenges that have arisen…
Researchers in South Korea have developed micro-robots (about 0.3 millimeters wide) that can be magnetically manipulated by physicians after injection to maximize stem cell delivery to the desired…
Researchers working within the University of New South Wales‘ (UNSW) Journey to the Centre of the Cell project have made great strides in 3D renderings that will allow…
Heat Biologics has devised a method intended to capture poly-antigens and present them to immunomodulatory mechanisms and revitalize the immune system, allowing it to target and annihilate cancer.
